Best Peptides for Gut Health in 2026
Peptides reach the gut in different ways: some rebuild absorptive surface after bowel resection, some change intestinal fluid secretion, some act on the barrier between cells, and some are represented here by studies in animals. This page reports the studies behind each one, who was enrolled, what was measured and what the paper found, with every citation retrieved through NCBI E-utilities on 9 August 2026. Short bowel syndrome, celiac disease, irritable bowel syndrome and prematurity are diagnosed conditions managed by a clinician, so read each result beside the population it came from.
2,203
Infants in the ELFIN lactoferrin trial (PMID 30635141)
1,394
Adults in the plecanatide constipation trial (PMID 28169285)
342
Adults in the larazotide celiac trial (PMID 25683116)
The Studies
One row per study, not one per compound. A peptide tested in more than one trial gets more than one row, because those papers enrolled different people and measured different endpoints.
| Compound | Population (n) | What was measured | Result | Design | PMID |
|---|---|---|---|---|---|
| Teduglutide (GLP-2 analogue) | 86 adults with short bowel syndrome and intestinal failure, 43 teduglutide and 43 placebo | Responders cutting weekly parenteral support volume by more than 20 percent at weeks 20 and 24 | 27 of 43 (63 percent) versus 13 of 43 (30 percent), P = .002. Mean parenteral support fell 4.4 versus 2.3 L per week, P below .001 | Randomised double-blind placebo-controlled, 24 weeks, the STEPS trial | 22982184 |
| Teduglutide (GLP-2 analogue) | 59 children with short bowel syndrome and intestinal failure, 24 lower dose, 26 higher dose, 9 standard of care | Patients reaching at least a 20 percent reduction in parenteral support at week 24 | 54.2 and 69.2 percent on the two teduglutide doses versus 11.1 percent on standard of care, both P below .05 | Phase 3, 24 weeks, two blinded dose arms plus a non-blinded standard-of-care arm | 31495952 |
| Linaclotide (guanylate cyclase-C agonist) | 804 adults with irritable bowel syndrome with constipation, mean age 44, 90 percent female | FDA combined responder: 30 percent abdominal pain improvement plus one added complete spontaneous bowel movement, over 12 weeks | 33.7 versus 13.9 percent, P below .0001, number needed to treat 5.1 (95 percent CI 3.9 to 7.1) | Phase 3 randomised double-blind placebo-controlled, 290 micrograms daily, 26 weeks | 22986437 |
| Linaclotide (guanylate cyclase-C agonist) | 1,276 adults with chronic constipation across two trials | Three or more complete spontaneous bowel movements per week plus a rise of one or more, for at least 9 of 12 weeks | 19.4 to 21.2 percent on linaclotide versus 3.3 to 6.0 percent on placebo, P below .01 for all comparisons | Two randomised 12-week double-blind placebo-controlled trials, 145 and 290 micrograms | 21830967 |
| Plecanatide (uroguanylin analogue) | 1,394 adults with chronic idiopathic constipation | Durable overall complete spontaneous bowel movement responders over 12 weeks | 21.0 percent (3 mg arm) and 19.5 percent (6 mg arm) versus 10.2 percent placebo, both P below .001 | Phase 3 multicentre double-blind placebo-controlled | 28169285 |
| Larazotide acetate (tight-junction regulator) | 342 adults with celiac disease on a gluten-free diet 12 months or longer, still symptomatic | Average on-treatment Celiac Disease Gastrointestinal Symptom Rating Scale score | The 0.5 mg three-times-daily arm separated from placebo, P = .022. The 1 and 2 mg arms did not differ from placebo | Multicentre randomised double-blind placebo-controlled, 12 weeks | 25683116 |
| Larazotide acetate (tight-junction regulator) | 184 adults with celiac disease on a gluten-free diet, given 2.7 g gluten daily for 6 weeks | Lactulose-to-mannitol permeability ratio, GSRS symptoms, and anti-tissue-transglutaminase IgA | No permeability-ratio difference. The 1 mg arm limited symptoms, P = .002. Anti-tTG IgA ratio 19.0 on placebo versus 5.78, 3.88 and 7.72 on the 1, 4 and 8 mg arms | Exploratory randomised double-blind placebo-controlled | 23163616 |
| Bovine lactoferrin (milk glycoprotein) | 2,203 infants born before 32 weeks of gestation, 37 UK hospitals, the ELFIN trial | Microbiologically confirmed or clinically suspected late-onset infection after 72 hours | 316 of 1,093 (29 percent) versus 334 of 1,089 (31 percent), adjusted risk ratio 0.95 (95 percent CI 0.86 to 1.04), P = .233 | Randomised placebo-controlled, enteral lactoferrin 150 mg per kg per day | 30635141 |
| Bovine lactoferrin (milk glycoprotein) | 305 preterm low-birth-weight neonates in Pakistan, three arms of placebo, 150 mg and 300 mg | Late-onset sepsis to 28 days (primary) and necrotising enterocolitis (secondary) | Culture-proven sepsis 7.8 percent placebo versus 0.98 percent at 150 mg (P = .020) and 4.9 percent at 300 mg (P = .390). NEC 3 versus 0 percent (P = .087) and 2 percent (P = .650) | Three-arm randomised double-blind placebo-controlled, 28 days | 40507041 |
| BPC-157 (pentadecapeptide) | Rats with cysteamine-induced colitis and a colon-to-colon anastomosis | Healing of the colitis lesion and of the surgical anastomosis | BPC 157 at 10 micrograms per kg or 10 nanograms per kg produced healing of both where saline controls did not | Controlled animal experiment, rat | 24304574 |
The doses each trial administered, each named with its paper:
Teduglutide 0.05 mg per kg once daily by subcutaneous injection, 24 weeks (PMID 22982184). Linaclotide 290 micrograms orally once daily (PMID 22986437). Plecanatide 3 or 6 mg orally once daily, 12 weeks (PMID 28169285). Larazotide acetate 0.5 mg three times daily, 12 weeks (PMID 25683116). Bovine lactoferrin 150 mg per kg per day enterally, to 34 weeks postmenstrual age (PMID 30635141).
Disclaimer: these are trial arms reported for comparison, not recommendations and not a titration schedule. Each was given under medical supervision and is a prescription decision made with a doctor.
Rebuilding Absorptive Surface
Teduglutide is a glucagon-like peptide 2 analogue. In the adult STEPS trial (PMID 22982184), 43 adults with short bowel syndrome and intestinal failure received it and 43 received placebo for 24 weeks, and 63 percent of the treated group cut their weekly intravenous feeding by more than 20 percent against 30 percent on placebo. The paediatric trial (PMID 31495952) enrolled 59 children and reported the same endpoint by dose. Both measured parenteral support volume, a hard clinical outcome in people who depend on it, rather than a surrogate marker. Approved peptide medicines used locally are listed on the therapeutic peptides guide.
Guanylate Cyclase-C Agonists
Linaclotide and plecanatide act on the guanylate cyclase-C receptor in the gut wall, drawing fluid into the lumen. The linaclotide trial in irritable bowel syndrome with constipation (PMID 22986437) enrolled 804 adults, 90 percent of them women, and its chronic-constipation trials (PMID 21830967) enrolled 1,276 more. Plecanatide, a uroguanylin analogue, was tested in 1,394 adults with chronic idiopathic constipation (PMID 28169285). Each used a responder definition combining bowel-movement frequency with symptom relief, and each reported diarrhoea as the main adverse event. For non-drug approaches to regularity, see the gut health guide, how to improve gut health, and best probiotics.
The Intestinal Barrier
Larazotide acetate is an oral peptide that acts on tight junctions, the seals between intestinal cells. In 342 adults with celiac disease still symptomatic on a gluten-free diet (PMID 25683116), the 0.5 mg arm separated from placebo on a symptom scale while the higher doses did not. In a separate gluten-challenge study of 184 adults (PMID 23163616), the lactulose-to-mannitol permeability ratio did not move, though symptoms and an anti-tissue-transglutaminase antibody marker did. The barrier idea these trials tested is covered on the leaky gut page, and celiac disease as an immune condition on the autoimmune and thyroid guide.
Lactoferrin In The Preterm Gut
Bovine lactoferrin is a milk glycoprotein studied for infection and necrotising enterocolitis in premature infants, a hospital setting under intensive care. The ELFIN trial (PMID 30635141) randomised 2,203 infants born before 32 weeks and recorded late-onset infection in 29 percent on lactoferrin against 31 percent on placebo, an adjusted risk ratio of 0.95 with a confidence interval running from 0.86 to 1.04. A smaller three-arm trial of 305 neonates (PMID 40507041) found lower culture-proven sepsis in its 150 mg arm and no significant difference in necrotising enterocolitis. These numbers belong to preterm newborns under neonatal care, not to adults.
BPC-157 In Animal Models
BPC-157 is a pentadecapeptide often discussed for gut healing. The record cited here is an animal study: rats with cysteamine-induced colitis and a surgical colon-to-colon join, in which the peptide healed both lesions where saline controls did not (PMID 24304574). That is a result in rats, and it is reported as such. The searches behind its inclusion are in the provenance section below. Background on the compound sits on the BPC-157 and KPV pages, and what to check before buying anything is on the COA verification guide.
How These Records Were Found
Each line states a query, an index and a date. A search result describes what a string matched in one database on one day, nothing beyond that.
- teduglutide AND short bowel syndrome AND randomized controlled trial[pt] in PubMed on 9 August 2026 returned 18 records.
- (linaclotide OR plecanatide) AND randomized controlled trial[pt] in PubMed on 9 August 2026 returned 56 records.
- larazotide AND clinical trial[pt] in PubMed on 9 August 2026 returned 6 records.
- bovine lactoferrin AND preterm AND randomized controlled trial[pt] in PubMed on 9 August 2026 returned 15 records.
- BPC 157 AND clinical trial[pt] in PubMed on 9 August 2026 returned 0 records, while (BPC 157 OR pentadecapeptide BPC 157) AND (colitis OR inflammatory bowel disease) returned 51. The record cited here carries no clinical-trial tag and is an animal study; that tag marks the boundary.
- (KPV OR lysine-proline-valine) AND clinical trial[pt] in PubMed on 9 August 2026 returned 7 records, and elafin AND clinical trial[pt] returned 20. A compound name bounds a search, so names, synonyms and MeSH entry terms were tried where known.
Frequently Asked Questions
Do these studies point to one peptide for gut health?+
No, and this page does not put them in order. Each row was measured in a different population: intravenous-feeding volume in adults with short bowel syndrome, bowel movements in adults with constipation, a symptom scale in celiac disease, infection rates in premature infants, and a healing endpoint in rats. A result in one of those groups does not carry over to another. Reading the population column first shows who each number belongs to.
Are teduglutide, linaclotide and plecanatide the same kind of drug?+
They are three different mechanisms. Teduglutide is a glucagon-like peptide 2 analogue that promotes growth of the intestinal lining, which is why its trials measured parenteral support in short bowel syndrome. Linaclotide and plecanatide are guanylate cyclase-C agonists that draw fluid into the bowel, which is why their trials counted spontaneous bowel movements in constipation. Same organ, unrelated targets and unrelated endpoints.
What does larazotide have to do with intestinal permeability or leaky gut?+
Larazotide acetate acts on tight junctions, the protein seals between intestinal cells that the permeability idea centres on. In the 6-week gluten-challenge study (PMID 23163616) the lactulose-to-mannitol permeability ratio did not separate from placebo, even though symptoms and an antibody marker did. So the barrier hypothesis was tested directly and the permeability endpoint was not met, a distinction the barrier concept is discussed further on the leaky gut guide.
Why is BPC-157 listed as an animal study?+
Because the record cited here is one: a rat experiment (PMID 24304574) in which the peptide healed cysteamine colitis and a surgical join where saline did not. That is a finding in rats, and it is reported as such, not extended to people. The searches behind its inclusion are listed in the provenance section.
Did lactoferrin prevent infection or NEC in premature babies?+
The results are mixed and belong to hospitalised preterm infants. The large ELFIN trial of 2,203 infants (PMID 30635141) found no reduction in late-onset infection, an adjusted risk ratio of 0.95 with a confidence interval crossing one. A smaller three-arm trial of 305 neonates (PMID 40507041) found lower culture-proven sepsis in its 150 mg arm but no significant difference in necrotising enterocolitis. Both were run in neonatal intensive care under close supervision.
What should someone take to a doctor after reading this?+
The population and the endpoint, not the compound name. Short bowel syndrome, celiac disease, irritable bowel syndrome with constipation and prematurity are all conditions diagnosed and managed by clinicians, and every dose printed here was given under medical supervision inside a trial. If you have a gut condition, the useful thing to bring is which condition and which measured outcome, so the conversation is about your situation rather than a peptide name.
Research And Sources
Every figure above comes from the record its PMID links to, retrieved through NCBI E-utilities on 9 August 2026. Responder percentages, confidence intervals and P values were read from each abstract; the lactoferrin sepsis and NEC counts come from the abstract of PMID 40507041. A compound appears in the table only where a citable study was found on the search date; the searches run are listed in the provenance section above.
Related Reading
For education only, not medical advice. Every dose figure here is a trial figure reported for comparison, not a recommendation, and every regimen above was administered under medical supervision inside its trial. Short bowel syndrome, celiac disease, irritable bowel syndrome and prematurity are managed by a doctor. Talk to a clinician before starting, stopping or changing anything.